Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest From Formycon AG

Fresenius And Formycon File Ustekinumab In US

Partners Fresenius Kabi and Formycon have submitted a US filing for their FYB202 ustekinumab biosimilar rival to Stelara.

Biosimilars Strategy

Formycon Submits Eylea Biosimilar For European Approval Following Strong Q3

Formycon has submitted its aflibercept candidate for European Medicines Agency consideration, following an incredibly strong Q3 which has put the company on track for a promising future.

Biosimilars Europe

Amgen Biosimilar For Stelara May Face Price Drop In Medicare Shortly After Launch; What’s A Follow-On To Do?

With J&J's Stelara set for Medicare negotiation, the fate of Amgen’s new ustekinumab interchangeable be a test case for concerns that the pricing program will significantly undercut incentives for developing biosimilars for blockbusters in the Medicare market.

Reimbursement Policy

Treatment For Maple Syrup Urine Disease Among 10 New EU Filings

REC 0545, for MSUD, and aztreonam-avibactam, for serious Gram-negative bacterial infections, are among the latest drugs that the European Medicines Agency has started reviewing for potential pan-EU marketing approval.

Review Pathway Europe
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule